Drugs / Pepinemab
Trials 13 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT05378464 | May 2022 → Aug 2026 | HER2 positive breast carcinoma | H. Lee Moffitt Cancer Center and Research Institute | Suspended | No outcome recorded |
| Phase 1 | NCT03769155 | Dec 2018 → Dec 2023 overdue | cutaneous melanoma | Emory University | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03690986 | Nov 2018 → Apr 2027 expected | head and neck squamous cell carcinoma | Emory University | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03425461 | Jun 2018 → Mar 2021 | cutaneous melanoma, metastatic melanoma | Jonsson Comprehensive Cancer Center | Terminated | No outcome recorded |
| Phase 1 | NCT03373188 | Dec 2017 → Oct 2021 | colorectal adenocarcinoma, metastasis from malignant tumor of colon, pancreatic adenocarcinoma | Emory University | Completed | No outcome recorded |
| Phase 1 | NCT01764737 | Dec 2012 → Nov 2014 | multiple sclerosis | Vaccinex Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01313065 | Jan 2011 → Jun 2014 | cancer | Vaccinex Inc. | Completed | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT05102721 | Dec 2022 → Dec 2028 expected | pancreatic adenocarcinoma | Vaccinex Inc. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04815720 | Aug 2021 → Jul 2024 | head and neck squamous cell carcinoma | Vaccinex Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT04381468 | Jul 2021 → Jun 2024 | Alzheimer disease | Vaccinex Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT03320330 | Jan 2018 → Dec 2020 | bone osteosarcoma, refractory malignant neoplasm, secondary malignant neoplasm | Children's Oncology Group | Completed | No outcome recorded |
| Phase 1/2 | NCT03268057 | Oct 2017 → Sep 2020 | non-small cell lung carcinoma | Vaccinex Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02481674 | Jul 2015 → Aug 2020 | Huntington disease | Vaccinex Inc. | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pepinemab | “VX15/2503 (pepinemab) is a humanized IgG4 monoclonal antibody and will be administered intravenously at a dose of 20 mg/kg.” NCT02481674 ↗ |
| Known as | Anti-sema4d monoclonal antibody vx15/2503 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297884 ↗ |
| Known as | moAb VX15/2503 | “moAb VX15/2503” NCT03425461 ↗ |
| Known as | VX-15 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297884 ↗ |
| Known as | VX15/2503 | “VX15/2503 (pepinemab) is a humanized IgG4 monoclonal antibody and will be administered intravenously at a dose of 20 mg/kg.” NCT02481674 ↗ |
| Action | Inhibit | “antibody neutralization of SEMA4D may represent a new therapeutic strategy” NCT01764737 ↗ |
| Modality | Monoclonal antibody | “The study drug, VX15/2503, is a monoclonal antibody that binds to the semaphorin 4D (SEMA4D; CD100) antigen.” NCT01313065 ↗ |
| Route | Intravenous | “to be administered intravenously” NCT01313065 ↗ |
| Target | SEMA4D | “binds to the semaphorin 4D (SEMA4D; CD100) antigen” NCT01313065 ↗ |